In-vitro Quantitative and Qualitative Evaluation of the Marketed Linagliptin and Aspirin Tablets Available in Bangladesh
Ahmed Sabbir1, SabihaEnam Spriha2, Shinthiya Abrar1, Adnan Bin Faisul Siddiqui1, Md. Shahidulla Kayser1, Md. Shariful Islam1*
Affiliation
1Biopharmaceutics & Pharmacokinetics Laboratory, Department of Pharmacy, State University of Bangladesh, Dhaka-1205, Bangladesh
2Department of Clinical Pharmacy & Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh
Corresponding Author
Shariful Islam, Department of Pharmacy, Assistant Professor, State University of Bangladesh, 77, Satmosjid Dhaka, Bangladesh Road, Dhanmondi, Tel: +8801937450445; Email: islam@sub.edu.bd
Citation
Islam, S. In-Vitro Quantitative and Qualitative Evaluationof the Marketed Linagliptin and Aspirin Tablets Available in Bangladesh (2019) J pharma pharmaceutics 6(1): 44-48.
Copy rights
© 2019 Islam, S. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Aspirin; Linagliptin; INN drug; ICH guideline
Abstract
The study was conducted with the aim to evaluate the quantitative and qualitative status of linagliptin and aspirin tablets manufactured in Bangladesh. Five and four different brand samples of linagliptin and aspirin tablets respectively were collected from retail pharmacy for spectrophotometric assay. Various physical parameters naming diameter and thickness determination, weight determination, friability, hardness, in vitro disintegration, dissolution percentage and potency were analyzed according to British Pharmacopoeia (BP) and United States Pharmacopoeia (USP). Out of total nine samples, only four samples met the BP specification of 95-105% of claimed potency. Four linagliptin and two aspirin samples complied with USP friability specification. Four samples of each generic drug met the USP specification for the in vitro disintegration and dissolution test.
